Invite someone you know to join Pharmalicensing.com
Change Password
PL Stealth Mode
Go Incognito on Pharmalicensing.
All interaction tracking will be disabled, rendering you invisible to other Pharmalicensing users and technology providers.
Stealth Mode currently OFF.
Included with Premium accounts. Add-on upgrade to Plus accounts.
Register
or
Sign in
to Save this opportunity, or Send an Inquiry.
You must be signed in to send an inquiry.
Please Register or Login to save this technology and benefit from all of Pharmalicensing's features.
Select to Save this to or Remove this from an Existing Collection
CD151: A Novel Anti-Inflammatory Regulator
Yeda R&D Co. LtdIsrael
Abstract ID: 1485
The surveillance of the body for foreign antigens is a critical function of the immune system. Accordingly, B and T lymphocytes continually patrol the body for foreign
Send an Inquiry
Introduction/Background
The surveillance of the body for foreign antigens is a critical function of the immune system. Accordingly, B and T lymphocytes continually patrol the body for foreign antigens by circulating from the blood, through tissues, into lymph nodes, and back to the blood. The continuous recirculation of lymphocytes and their movement from the blood into peripheral tissues is a central feature of immune surveillance, but also contributes to the pathogenesis of inflammatory diseases, autoimmune diseases, and the development and progression of allergic responses.
Aims/Hypothesis
We are investigating the down-regulation of CD151 as a means for treating inflammation.
Results
In the present invention it has been uncovered that CD151 expression in T cells plays a key role in T cell migration and homing to the lymph nodes. The impaired homing of T lymphocytes to the peripheral lymph nodes results in attenuated progression of both asthma and adjuvant arthritis. Thus, a blocking agent for the activity or expression of CD151 can exert global suppressive effects on T-cell trafficking and differentiation within peripheral lymph nodes, and may be clinically beneficial as an anti-inflammatory agent.
Conclusion
The current invention targets the activity or expression of CD151, a molecule role involved in T cell migration, for treating inflammation.
Relevance/Opportunity
Treatment of inflammation and other conditions which involve an inflammatory response (eg,. autoimmune diseases, allergic diseases, graft rejection diseases). Please enquire quoting reference no. 1485 regarding licensing or codevelopment partnerships.
Clinical Trial Information (0)Hide
FEATURED
Last Updated May 2015
MECHANISM
PRECLINICAL
CORPORATION
Yeda R&D Co. Ltd
Weizmann Institute of Science
P.O Box 95,
Rehovot 76100
Israel